Cancer Singapore | National University Cancer Institute, Singapore (NCIS) > Research > The Haematology-Oncology Research Group (HORG)

The Haematology-Oncology Research Group (HORG)

The Haematology-Oncology Research Group (HORG) is the research arm of the National University Cancer Institute, Singapore (NCIS). The HORG consists of haematologists and oncologists committed to the research of cancers endemic to Asia, with a special interest in the development of novel drugs for cancer treatment as well as improving existing treatments. The HORG strives to provide the best treatment options and care for patients through continuous research. In the area of pharmacogenetics, the research group is established as one of the global teams studying inter-ethnic variability in anti-cancer drugs. With a strong grounding in clinical pharmacology and molecular biology, combined with technology and clinical expertise, the HORG is also involved in novel clinical trials especially in early-phase drug development.

The HORG is also part of the Cancer Therapeutics Research Group (CTRG) that was formed in 1997 under the leadership of Professor John Wong of the NCIS and Professor James Bishop of the Sydney Cancer Centre with the aim of conducting clinical trials in the Asia-Pacific region. The CTRG is a member of a large consortium of US-based institutions led by the Mayo Clinic that also conducts research in novel cancer drugs.

Such collaborations allow the NCIS access to a large library of novel molecular agents made available from the US National Cancer Institute. Over the years, the HORG has conducted clinical trials involving patients with cancers such as nasopharyngeal carcinoma, thyroid cancer, multiple myeloma, hepatocellular carcinoma, gastric cancer and breast cancer.



Contact Information



Telephone: (65) 6772 4619


Back to Top